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Abstract
Background: Cardiac dysfunction is increasingly recognized in patients with liver cirrhosis. Nevertheless, the
presence or absence of structural alterations such as diffuse myocardial fibrosis remains unclear. We aimed to
investigate myocardial structural changes in cirrhosis, and explore left ventricular (LV) structural and functional
changes induced by liver transplantation.
Methods: This study included 33 cirrhosis patients listed for transplantation and 20 healthy controls. Patients
underwent speckle-tracking echocardiography and cardiovascular magnetic resonance (CMR) with extracellular
volume fraction (ECV) quantification at baseline (n = 33) and 1 year after transplantation (n = 19).
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: cardiman73@gmail.com; hkkim73@snu.ac.kr;
pindra@empal.com
1Division of Cardiology, Department of Internal Medicine and Cardiovascular
Center, Section of Cardiovascular Imaging, Seoul National University Hospital,
103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea
3Division of Gastroenterology, Department of Internal Medicine and Liver
Research Institute, Seoul National University College of Medicine, 103
Daehak-ro, Jongno-gu, Seoul 03080, South Korea
Full list of author information is available at the end of the article
Kim et al. Journal of Cardiovascular Magnetic Resonance           (2020) 22:25 
https://doi.org/10.1186/s12968-020-00622-2
(Continued from previous page)
Results: CMR-based LV ejection fraction (CMRLV-EF) and echocardiographic LV global longitudinal strain (LV-GLS)
demonstrated hyper-contractile LV in cirrhosis patients (CMRLV-EF: 67.8 ± 6.9% in cirrhosis vs 63.4 ± 6.4% in healthy
controls, P = 0.027; echocardiographic GLS: − 24.2 ± 2.7% in cirrhosis vs − 18.6 ± 2.2% in healthy controls, P < 0.001).
No significant differences in LV size, wall thickness, mass index, and diastolic function between cirrhosis patients
and healthy controls were seen (all P > 0.1). Only one of the cirrhosis patients showed late gadolinium
enhancement. However, cirrhosis patients showed a higher ECV (31.6 ± 5.1% vs 25.4 ± 1.9%, P < 0.001) than healthy
controls. ECV showed a positive correlation with Child-Pugh score (r = 0.564, P = 0.001). Electrocardiogram-based
corrected QT interval was prolonged in cirrhosis (P < 0.001). One-year post-transplantation, echocardiographic LV-
GLS (from − 24.9 ± 2.4% to − 20.6 ± 3.4%, P < 0.001) and ECV (from 30.9 ± 4.5% to 25.4 ± 2.6%, P = 0.001) moved to
the normal ranges. Corrected QT interval decreased after transplantation (from 475 ± 41 to 429 ± 30 msec, P = 0.001).
Conclusions: Myocardial extracellular volume expansion with augmented resting LV systolic function was
characteristic of cirrhotic cardiomyopathy, which normalizes 1-year post-transplantation. Thus, myocardial
extracellular expansion represents a structural component of myocardial changes in cirrhosis.
Keywords: Extracellular volume fraction, Cardiovascular magnetic resonance, Left ventricle, Global longitudinal
strain, Cirrhosis,
Background
Liver cirrhosis is associated with chronic dysfunction in
the cardiovascular system [1–4]. Cardiac dysfunction is
usually subclinical at rest, but can be clinically manifest,
especially when rapid blood volume shift occurs, for ex-
ample in transjugular intrahepatic portosystemic shunt
or liver transplantation, which subsequently contributes
to cardiovascular complications [5–7]. This cardiac con-
dition in cirrhosis is referred to as cirrhotic cardiomyop-
athy. This unique cardiomyopathy is characterized by
blunted contractile response to stress stimuli, diastolic
dysfunction, and electrophysiological abnormalities in
the absence of gross cardiac diseases [1–4]. Since myo-
cardial changes observed in cirrhosis were mostly based
on echocardiography, earlier studies mainly focused on
functional and hemodynamic changes without co-
demonstration of anatomical changes. Thus, myocardial
structural changes in cirrhosis remain largely unclear, al-
though diffuse myocardial fibrosis (DMF) was suggested,
mostly in patients with alcoholic cirrhosis [8, 9]. There-
fore, whether functional changes on echocardiography
are secondary to myocardial structural changes, or are
simply collateral phenomena resulting from cirrhosis
-induced hemodynamic alteration without myocardial
structural changes remains to be established.
Cardiovascular magnetic resonance (CMR) with late gado-
linium enhancement (LGE) is a widely utilized non-invasive
imaging protocol for myocardial tissue characterization.
However, a drawback of LGE is its insufficient sensitivity in
detecting reversible, early stage diffuse interstitial fibrosis or
DMF [10, 11]. Recently, extracellular volume fraction (ECV)
quantification by CMR T1 mapping technique has been in-
troduced to evaluate DMF in vivo. Previous studies demon-
strated that ECV reliably reflect the degree of DMF and,
more importantly, is associated with prognosis in various
cardiac diseases [12–14]. Thus, in this study, we hypothe-
sized that myocardium in liver cirrhosis has structural alter-
ations such as DMF, which could be effectively addressed by
CMR. We also attempted to relate the structural changes to
functional or hemodynamic changes on echocardiography.
Finally, we evaluated whether these changes could be re-
versed by liver transplantation.
Methods
Study population
From March 2016 to December 2017, 36 patients with
liver cirrhosis of various etiologies who were listed on
the transplant waitlist were prospectively enrolled, of
whom three (8.3%) were excluded as they failed to
undergo CMR due to acute clinical deterioration. All in-
cluded patients had been referred to the cardiology de-
partment for cardiac evaluation before transplantation.
Liver cirrhosis was confirmed based on clinical, labora-
tory, and ultrasonographic findings [15–17]. Patients
with any of the following were systematically excluded:
aged < 18 years, decreased kidney function (estimated
glomerular filtration rate < 30mL/min/1.73 m2), docu-
mented history of cardiovascular diseases including cor-
onary artery disease, and other forms of myocardial
disease, and acute liver failure without cirrhosis. All pa-
tients underwent computed tomographic coronary angi-
ography or invasive coronary angiography as a routine
preoperative assessment. The absence of a significant
coronary artery disease (> 50% luminal stenosis) was
verified. Electrocardiogram (ECG), transthoracic echo-
cardiography, and CMR were performed at baseline (n =
33) and repeated at 1 year after transplant (n = 19). Clin-
ical data on baseline characteristics were collected. Liver
cirrhosis severity was categorised according to the
Child-Pugh score. For comparison, 20 subjects without
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any cardiovascular disease or cardiovascular disease risk
factors were included as healthy controls. This study was
conducted according to the principles of the Declaration
of Helsinki and approved by the Institutional Review
Board of our institution. Written informed consent was
obtained from all participants.
Transthoracic echocardiography and ECG
Echocardiographic and ECG examinations were con-
ducted as part of the preoperative cardiac evaluation.
Echocardiographic data were obtained with commer-
cially available equipments (Vivid 7, General Electric
Healthcare, Horten, Norway; E9, Philips Healthcare, An-
dover, Massachusetts, USA; Acuson SC2000, Siemens
Medical Solutions, Mountain View, California, USA).
Conventional echocardiographic parameters were mea-
sured by experienced sonographers. Left ventricular (LV)
ejection fraction (LVEF) was calculated in accordance
with the American Society of Echocardiography guide-
line [18]. To assess LV diastolic function, the transmitral
inflow peak early (E) and late (A) diastolic velocities,
early septal mitral annular diastolic velocity (e’), left
atrial (LA) volume index (LAVI), and peak tricuspid re-
gurgitation velocity were recorded. LA volumes were
measured using biplane area-length method at the end-
ventricular systole, and LA volume index (LAVI) was
calculated as LA volume divided by body surface area. LV
diastolic function was graded based on the 2016 recom-
mendation [19]. Contrast echocardiography using agitated
saline was performed through a left antecubital intraven-
ous line to assess the presence or absence of intrapulmon-
ary shunt. Intrapulmonary shunt was confirmed when
bubbles were visualized in the LA and/or LV > 3 beats
after its appearance in the right atrium. Data on the LV
global longitudinal strain (GLS) and global circumferential
strain (GCS) were acquired using two-dimensional
speckle-tracking echocardiography based on the guideline
[20, 21]. Speckle-tracking echocardiography was used to
assess strain values because it has been already incorpo-
rated into the daily clinical practice and is now the widely
available technique of choice for the assessment of LV
strain [20, 21]. LV GLS and GCS measurement and ana-
lyses were performed using commercially available soft-
ware (TomTec, Image Arena 4.6, Munich, Germany).
On ECG QT interval was measured from the start of
the Q wave to the end of the T-wave in lead II. To ad-
just for the heart rate, corrected QT (QTc) interval was
calculated by dividing the QT interval by the square root
of the R-R interval.
CMR
CMR was performed using a 3 T CMR system (MAGNE-
TOM Skyra; Siemens Healthineers, Erlangen, Germany)
equipped with six-channel phased-array coils [22]. After
acquiring scout images for localization, balanced steady-
state free precession cine images were obtained during
breath-holding. To include the entire LV volume, LV
short-axis images (6-mm thickness with 4-mm intersection
gap) were acquired at 10-mm intervals from the base to
apex using retrospective ECG gating with the following pa-
rameters: repetition time /echo time, 2.8–3.2msec/1.4–1.6
msec; flip angle, 80°; temporal resolution, 42msec; field of
view, 240 × 300mm; and matrix, 256 × 150. LV end-
diastolic volume (EDV), end-systolic volume (ESV) vol-
umes, and LVEF were measured from the cine images. LV
stroke volume, cardiac index and mass index were subse-
quently calculated.
ECV calculation was performed as follows. After ac-
quiring cine images, a mid-ventricular short-axis section
at the papillary muscle level was obtained using the
modified Look-Locker inversion-recovery sequence, with
three images in the first two Look-Locker segments and
five images for the third inversion (the “3–3-5” standard
protocol) [23]. Finally, 11 images acquired in 17 heart-
beats were obtained, and in-line motion correction and
map generation were performed. The following readout
parameters were used: section thickness, 6 mm; 2.5/1.1;
6/8 partial Fourier acquisition; field-of-view, 240 × 300
mm; and matrix, 192 × 125. Region of interest was drawn
manually at the mid-ventricular septum and LV blood
pool on pre- and post-contrast T1 mapping images to
measure the ECV. Care was taken to draw the region-of-
interest on the compact myocardium and to not include
the border of the myocardium because it shows gradual
changes in T1 values due to both partial volume aver-
aging artifact and registration error, even after motion
correction. One radiologist (E-A Park, with > 10 years of
CMR experience) performed all measurements, and
myocardial T1 could be measured reliably with one large
region of interest on all images. Intra- and inter-
observer variability was previously reported at our insti-
tution for this measurement [12]. ECV was estimated as
follows: ECV = (1 – hematocrit) × [1/T1 myocardium post -
1/T1myocardium pre]/[1/T1 blood post - 1/T1blood pre] [24].
To evaluate irreversible myocardial fibrosis, the presence
or absence of LGE was assessed. LGE images were ac-
quired 10min after intravenous gadolinium administra-
tion (0.2mmol/kg Magnevist; Schering, Berlin, Germany),
immediately followed by 20mL saline flush. The protocol
for obtaining LGE images was as follows: slice thickness,
6 mm; interslice gap, 4mm; TR, 9.1 msec; TE, 42msec;
flip angle, 13 degrees; and in-plane resolution, 1.4 × 1.9
mm. LGE images from the same image planes as those in
the cine images were acquired using inversion recovery
segmented spoiled-gradient echo and phase-sensitive in-
version recovery sequences. The most appropriate inver-
sion time was set to null the normal myocardium, which
was typically between 250 and 300msec, in both pre- and
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post-transplant CMR examinations. LGE CMR images
were analyzed by an experienced radiologist (E-A Park),
who was blinded to the patients’ information.
At the last stage of this study, myocardial T2 mapping
data was acquired in 6 patients using adiabatic T2-
prepared fast low-angle shot (FLASH) technique. Three
single-shot FLASH images with different T2 preparation
times were acquired as follow: echo time (ms): 0, 30, 55
respectively; slice thickness 6mm; TR, 2.4 msec; TE, 1.0
msec; flip angle, 12 degrees; receiver bandwidth 1184Hz/
pixel; field of view, 288 × 360mm; and matrix, 144 × 192.
Statistical analysis
Baseline characteristics are described as number and
percentages for categorical variables, and mean ± stand-
ard deviation for continuous variables. Patient character-
istics were compared between groups using a chi-square
or Fisher’s exact test for categorical variables, and Stu-
dent’s t test or Mann-Whitney U test for continuous
variables, as appropriate. Changes in echocardiographic,
ECG, and CMR parameters between pre- and post-
transplant were compared using paired t-test or Wil-
coxon signed rank test. Pearson’s correlation coefficient
was used to evaluate the relationship between the rele-
vant parameters and Child-Pugh score. A partial correl-
ation analysis between ECV and Child-Pugh score was
performed while controlling for cardiac index. All statis-
tical analyses were performed using SPSS (v22.0 Statis-
tical Package for the Social Sciences, International
Business Machines, Inc., Armonk, New York, USA). A
P-value < 0.05 was considered statistically significant.
Results
Baseline characteristics
A total of 33 patients were analyzed in the final analysis.
The patients’ baseline characteristics are summarized in
Table 1. Mean age of cirrhosis patients was 56.3 ± 9.9
years and 25 (75.8%) were men. The etiology of cirrhosis
was viral in 20 patients (60.6%), alcoholic in 9 (27.3%),
and autoimmune hepatitis in 2 (6.1%). Most patients
(n = 23, 69.7%) were in Child-Pugh class C and their
heart rate was higher than that of patients with Child-
Pugh class A/B (P = 0.002). There were no significant
differences in the prevalence of hypertension and dia-
betes mellitus and in the levels of hemoglobin and cre-
atinine between the Child-Pugh class A/B and Child-
Pugh class C groups. No significant difference in cardio-
vascular medications at the time of CMR except for
beta-blockers was noted.
Echocardiographic and ECG parameters in cirrhosis
Comparisons of echocardiographic and ECG parameters
are shown in Table 2. No significant differences in LV
size, LV wall thickness, and Doppler transmitral inflow
patterns were found between the healthy controls
(65.0 ± 14.8 years; men, 11 (55%)) and cirrhosis patients
were observed. Notably, LVEF, a conventional index for
LV systolic function, was significantly higher in cirrhosis
patients than in normal controls (P = 0.049), indicating a
hyper-contractile state in cirrhosis. Resting hyper-
contractile state in cirrhosis was corroborated by a sig-
nificant augmentation in GLS (− 24.2 ± 2.7% in cirrhosis
vs − 18.6 ± 2.2% in the healthy controls, P < 0.001). LAVI
and E/e’ ratio were significantly higher in cirrhosis pa-
tients than in the normal controls, suggesting impaired
LV diastolic function in cirrhosis patients. No significant
difference in E/A ratio and deceleration time was found.
LV diastolic function in cirrhosis patients could not be
classified into one category in 15 patients (45.5%) when
the 2016 guideline was applied [19]. In addition, the sig-
nificant overlap of LA dimension, LAVI and even E/e’ ra-
tio between cirrhosis patients and healthycontrols were
observed (Fig. 1a, b, and c). Estimated pulmonary artery
systolic pressure was significantly higher in patients with
Child-Pugh class C than in patients with Child-Pugh class
A/B (P = 0.040). As expected, QTc interval was signifi-
cantly prolonged in cirrhosis patients (P < 0.001). Most
ECG and echocardiographic parameters between Child-
Pugh class A/B and Child-Pugh class C showed no statis-
tical differences. A significant positive linear correlation
was observed between QTc interval and Child-Pugh score
(r = 0.388, P = 0.025).
CMR in cirrhosis patients
CMR-based hemodynamic parameters are shown in
Table 3. LVEF was significantly higher in cirrhosis patients
(P = 0.027), mainly driven by a larger EDV, rather than by
a smaller ESV. Moreover, LV stroke volume (99.5 ± 29.3
vs 85.2 ± 15.1mL, P = 0.025) and cardiac index (4.3 ± 1.1
vs 3.3 ± 0.7 L/min/m2, P = 0.002) were greater in cirrhosis
patients, again supporting hyper-dynamic circulation in
cirrhosis [2]. No differences in hemodynamic parameters
between Child-Pugh class A/B and class C groups were
found, although cardiac index tended to be higher in
Child-Pugh class C group (P = 0.073). With Child- Pugh
score as a continuous variable, a positive trend in relation
to cardiac index was observed (r = 0.337, P = 0.06). There
were no significant differences in terms of LV mass index
and LV mass/LV EDV ratio between cirrhosis patients
and the healthy control group.
Focal subendocardial LGE was detected at the mid-
anterior segment in one cirrhosis patient, whose coron-
ary arteries were normal on invasive coronary angiog-
raphy. No LGE was found in the healthy controls. Native
T1 value of myocardium was significantly longer in pa-
tients with cirrhosis compared with healthy subjects
(P = 0.001; Table 3). However, there was no statistically
significant correlation between Child-Pugh score (as a
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continuous variable) and native T1 value in cirrhosis
(P = 0.87). Cirrhosis patients had a significantly higher
ECV (31.6 ± 5.1 vs 25.4 ± 1.9, P < 0.001; Table 3 and
Fig. 2a), mainly driven by the cirrhosis patients with
Child-Pugh class C (Table 3 and Fig. 2b). Besides, ECV
was significantly higher in Child-Pugh class C than
class A/B (33.6 ± 4.4 vs 27.2 ± 3.4, P = 0.001; Table 3
and Fig. 2b). Furthermore, a significant correlation be-
tween Child-Pugh score and ECV was noted (r = 0.564,
P = 0.001; Fig. 3). Even after adjusting for cardiac index,
the correlation between ECV and Child-Pugh score
remained significant (r = 0.427, P = 0.019). The pre-
transplant native T2 values measured in 6 patients at
the last stage of this study were within normal range in
all 6 patients (100%), whereas pre-transplant ECV was
more than 30.0% in 4/6 patients (66.7%) (Table 4).
Changes in echocardiographic and CMR parameters 1
year after transplant
A total of 28 patients underwent transplant, of which four
(14.3%) died after transplantation. Three patients died of
sepsis-associated heart failure within 6months after trans-
plant, and 1 patient died of heart failure 9months after
transplant. Patients who died after transplant were older,
and had a lower pre-transplant CMR cardiac index (Add-
itional file 1: Tables S1-S3). Of the 24 patients who survived
transplant, 19 patients underwent echocardiography, ECG,
and CMR 1-year post-transplant. Five patients refused
follow-up examinations 1 year after transplant. Pre- and
post- transplant ECG, echocardiographic and CMR param-
eters of the 19 patients were compared (Table 5 and Fig. 4).
ECV showed a significant decrease 1 year after transplant
(P < 0.001; Fig. 4a). Both LV end-diastolic diameter on
Table 1 Baseline clinical characteristics of 33 patients with liver cirrhosis
All Child-Pugh class A/B Child-Pugh class C P
valueN = 33 N = 10 N = 23
Age (years) 56.3 ± 9.9 58.8 ± 7.3 55.3 ± 10.8 0.355
Male (n, %) 25 (75.8%) 9 (90.0%) 16 (69.6%) 0.208
Systolic blood pressure (mmHg) 113.47 ± 14.0 111.5 ± 7.6 114.4 ± 16.2 0.601
Diastolic blood pressure (mmHg) 66.3 ± 12.3 60.9 ± 9.0 68.8 ± 12.9 0.094
Heart rate (/min) 73.6 ± 15.7 63.3 ± 9.1 78.0 ± 16.0 0.002
Cirrhosis etiology (n, %) 0.296
Viral 20 (60.6%) 8 (80.0%) 12 (52.2%)
HBV 17 (51.5%) 6 (60.0%) 11 (47.8%)
HCV 3 (9.1%) 2 (20.0%) 1 (4.3%)
Alcoholic 9 (27.3%) 1 (10.0%) 8 (34.8%)
Autoimmune hepatitis 2 (6.1%) 0 (0%) 2 (8.7%)
Cryptogenic 2 (6.1%) 1 (10.0%) 1 (4.3%)
Child-Pugh score 9.8 ± 2.4 6.8 ± 1.3 11.1 ± 1.2 < 0.001
MELD score 18.8 ± 7.4 11.1 ± 2.1 22.1 ± 6.3 < 0.001
Underlying diseases (n, %)
Hypertension 8 (24.2%) 4 (40.0%) 4 (17.4%) 0.164
Diabetes mellitus 9 (27.3%) 4 (40.0%) 5 (21.7%) 0.279
Medication (n, %)
Beta-blockers 8 (24.2%) 6 (60.0%) 2 (8.7%) 0.002
Diuretics 17 (51.5%) 4 (40.0%) 13 (56.5%) 0.383
ACEI/ARB 3 (9.1%) 2 (20%) 1 (4.3%) 0.151
Laboratory examination
Hemoglobin (g/dL) 10.6 ± 1.6 11.4 ± 1.6 10.2 ± 1.5 0.050
Creatinine (mg/dL) 0.9 ± 0.4 0.8 ± 0.2 0.9 ± 0.4 0.565
Bilirubin (mg/dL) 7.5 ± 8.5 1.7 ± 0.6 10.0 ± 9.1 < 0.001
Albumin (g/dL) 2.9 ± 0.4 3.2 ± 0.4 2.7 ± 0.4 0.002
PT (INR) 1.9 ± 1.0 1.3 ± 0.2 2.1 ± 1.1 0.001
Values are shown as number (%) or mean ± standard deviation
HBV hepatitis B virus, HCV hepatitis C virus, MELD the model for end stage liver disease, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor
blockers, PT prothrombin time, INR international normalized ratio
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echocardiography and LV EDV on CMR significantly
decreased 1-year post- transplant (P = 0.003 and
0.001, respectively). Although CMR LVEF showed no
significant changes 1-year post-transplant (P = 0.382),
LV GLS (from − 24.9 ± 2.4% to − 20.6 ± 3.4%, P <
0.001; Fig. 4b) and GCS (from − 28.4 ± 3.6% to −
24.6 ± 4.2%, P = 0.011; Fig. 4c) on echocardiography sig-
nificantly decreased 1 year after transplant. LV mass index
by CMR showed a significant decrease 1 year after trans-
plant, and LV concentricity by LV mass/LV EDV ratio
showed a significant increase (Table 5 and Fig. 5). QTc
interval also decreased (from 475 ± 41msec to 429 ± 30
msec, P = 0.001; Fig. 4d). E/A ratio was significantly de-
creased 1-year post- transplant (from 1.2 ± 0.5 to 0.9 ± 0.3,
P = 0.002). E/e’ ratio was significantly decreased, as well
(11.0 ± 0.23 to 8.9 ± 2.9, P = 0.030).
Discussion
Hemodynamic adaptation in liver cirrhosis was first re-
ported in 1953 [25]. Thereafter, cardiac dysfunction in
Table 2 Baseline echocardiographic and electrocardiographic parameters
Healthy controls Cirrhosis Child-Pugh class A/B Child-Pugh class C P
value†
P
value*N = 17 N = 33 N = 10 N = 23
LVEF (%) 62.7 ± 5.6 66.0 ± 5.2 66.4 ± 3.5 65.8 ± 5.8 0.049 0.777
LV EDD (mm) 47.9 ± 4.0 48.0 ± 5.5 48.6 ± 4.8 47.7 ± 5.9 0.969 0.686
LV ESD (mm) 29.7 ± 4.3 28.0 ± 4.3 28.2 ± 3.4 28.0 ± 4.7 0.206 0.905
LV wall thickness (mm) 9.1 ± 0.9 8.9 ± 1.3 9.2 ± 1.3 8.8 ± 1.3 0.747 0.456
E/A ratio 0.9 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 1.2 ± 0.5 0.165 0.431
Deceleration time (msec) 210.2 ± 30.2 212.3 ± 41.0 232.3 ± 39.6 203.2 ± 39.1 0.857 0.061
E/e’ ratio 8.6 ± 2.5 10.4 ± 2.5 10.8 ± 2.4 10.2 ± 2.5 0.018 0.431
Diastolic function 0.474 0.776
Normal 9 (52.9%) 17 (51.5%) 5 (50.0%) 12 (52.2%)
Indeterminate 7 (41.2%) 15 (45.5%) 5 (50.0%) 10 (43.5%)
Grade 1 1 (5.9%) 0 (0%)
Grade 2 0 (0%) 1 (3.0%) 0 (0%) 1 (4.3%)
LA dimension (mm) 38.2 ± 3.8 43.7 ± 7.7 47.1 ± 8.9 42.2 ± 6.7 0.008 0.094
LAVI (mL/m2) 39.8 ± 7.8 47.3 ± 11.2 45.6 ± 12.0 48.0 ± 11.0 0.020 0.565
Estimated PASP (mmHg) 32.1 ± 3.1 33.8 ± 5.3 31.0 ± 2.9 35.1 ± 5.7 0.348 0.040
GLS (%) −18.6 ± 2.2 −24.2 ± 2.7 −25.2 ± 2.7 −23.8 ± 2.6 < 0.001 0.170
GCS (%) −26.1 ± 4.7 −27.8 ± 5.1 −27.7 ± 5.1 −27.8 ± 5.2 0.254 0.950
Positive agitated saline test (n, %) 0 (0%) 22 (66.7%) 6 (60.0%) 16 (69.6%) – 0.592
QTc interval (msec) 410.5 ± 8.6 470.3 ± 36.1 453.7 ± 19.9 477.6 ± 39.4 < 0.001 0.081
LVEF left ventricular ejection fraction, EDD end-diastolic diameter, ESD end-systolic diameter, E peak early diastolic mitral inflow velocity, A peak late diastolic
transmitral peak velocity, e’ early diastolic mitral annular velocity, LA left atrium, LAVI left atrial volume index, PASP pulmonary artery systolic pressure, GLS global
longitudinal strain, GCS global circumferential strain, QTc corrected QT interval
†P value between normal and all liver cirrhosis groups
*P value between Child-Pugh class A/B and Child-Pugh class C
Fig. 1 Left ventricular diastolic functional parameters in patients with cirrhosis and normal controls. LA, left atrium; LAVI, left atrial volume index
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cirrhosis has gained increasing attention, leading to coin-
ing the term ‘cirrhotic cardiomyopathy’. Functional and
hemodynamic changes have been repeatedly described [4,
5, 26–28]; however, there has been a paucity of data re-
garding myocardial structural alterations in an in vivo set-
ting. Here, we adopted CMR to demonstrate myocardial
structural changes in transplant. CMR is best suited for
myocardial tissue characterization in vivo, thanks to its
unique LGE and T1 mapping techniques [12, 14, 22, 23].
Speckle-tracking echocardiography-derived GLS was also
assessed to sensitively detect LV systolic functional
changes, because it is known as the most sensitive and ac-
curate index for systolic function [29, 30].
The main findings of this study are summarized as follows
and in Fig. 6: First, ECV was significantly increased in cir-
rhosis patients and showed a positive correlation with cir-
rhosis severity (assessed by Child-Pugh score; Fig. 3).
Moreover, the QTc correlated with Child-Pugh score and
ECV. These findings support that cirrhosis severity, myocar-
dial structural changes, and myocardial electrical alterations
are closely linked to each other. Second, assessment of
resting LV diastolic function by echocardiography was im-
practical because almost half of cirrhosis patients (45.5%)
could not be conclusively categorised based on the current
guideline [19]. Finally, pre-transplant echocardiographic
GLS was significantly augmented at rest, which recovered to
the normal ranges 1 year after transplant. ECV and QTc
normalization was also observed 1 year after transplant.
Therefore, increased ECV and augmented GLS are consid-
ered two characteristic features of cirrhotic cardiomyopathy.
To the best of our knowledge, this is the first study to
evaluate myocardial structural and functional characteris-
tics before and after liver transplant using both CMR and
speckle-tracking echocardiography in cirrhosis patients.
Table 3 Baseline cardiovascular magnetic resonance parameters








N = 20 N = 33 N = 10 N = 23
LVEF (%) 63.4 ± 6.4 67.8 ± 6.9 66.1 ± 6.5 68.5 ± 7.1 0.027 0.368
LV EDV (mL) 135 ± 20 150 ± 47 153 ± 42 149 ± 50 0.101 0.811
LV ESV (mL) 51 ± 16 49 ± 21 52 ± 18 48 ± 23 0.752 0.604
Stroke volume (mL) 85 ± 15 100 ± 29 101 ± 28 99 ± 30 0.025 0.845
Cardiac index (L/min) 3.3 ± 0.7 4.3 ± 1.1 3.8 ± 1.0 4.5 ± 1.1 0.002 0.073
LV mass index (g/m2) 76.8 ± 13.0 70.7 ± 15.8 70.1 ± 13.0 71.0 ± 17.1 0.138 0.858
LV mass/LV-EDV ratio 0.9 ± 0.2 0.8 ± 0.3 0.8 ± 0.3 0.9 ± 0.2 0.126 0.875
Presence of LGE 0 (0%) 1 (3.0%) 0 (0%) 1 (4.3%) 0.432 0.503
Native T1 (msec) 1174 ± 65 1228 ± 79 1216 ± 60 1233 ± 87 0.001 0.584
ECV (%) 25.4 ± 1.9 31.6 ± 5.1 27.2 ± 3.4 33.6 ± 4.4 < 0.001 0.001
LVEF left ventricular ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, LGE late gadolinium enhancement, ECV extracellular volume fraction
†P value between normal and all LC groups
*P value between Child-Pugh class A/B and Child-Pugh class C
Fig. 2 Diffuse myocardial fibrosis assessed by ECV in patients with liver cirrhosis (LC) and normal controls. a Extracellular volume (ECV) was
significantly higher in cirrhosis patients. b Progressive increase in ECV was demonstrated from healthy controls to patients with Child-Pugh class
C (P < 0.001)
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Echocardiographic and electrophysiological components
in the diagnosis of cirrhotic cardiomyopathy
Patients with cirrhosis experience a series of cardiovas-
cular changes, including splanchnic arterial vasodilation
with associated reduced systemic vascular resistance,
neurohumoral axes dysfunction, and myocardial func-
tional/electrophysiological changes. Apart from redistri-
bution of circulating blood volume to the splanchnic
bed, reduced systemic vascular resistance results in re-
duced central blood volume, subsequently leading to a
resting hyper-dynamic syndrome. Thus, the resting
hyper-dynamic state in cirrhosis by the hyper-contractile
LV is considered an appropriate adaptive process to
compensate for reduced central blood volume [1, 31].
This study also noted that LVEF was significantly greater
in cirrhosis patients, which is supported by significantly
increased echocardiographic GLS pre-transplant. No pa-
tient showed an LVEF < 55%, suggesting that the abso-
lute number of resting LVEF itself is less clinically
helpful to define cirrhotic cardiomyopathy. LV stain is
more sensitive than LVEF to subtle changes in LV myo-
cardial performance [29, 30]. We found that GCS in cir-
rhosis patients was not different from that in the normal
controls, whereas GLS showed significant differences be-
tween the two groups. This finding suggests that GLS
better reflects subtle changes in LV systolic performance,
as suggested previously [29, 30, 32, 33].
LV diastolic dysfunction at rest was proposed as a
diagnostic and supportive criterion for cirrhotic cardio-
myopathy [2]. In this study, LAVI was greater in cirrho-
sis, indicating prolonged LV diastolic dysfunction in
cirrhosis patients. Although E/e’ ratio was significantly
higher in cirrhosis patients, it fell between 8 and 15, bor-
derline values that cannot be used for clear differenti-
ation between normal and increased LV filling pressure
[34]. However, elevated LV filling pressure seemed to be
present because E/A ratio was also > 1 in cirrhosis pa-
tients [35]. However, the significant overlap of LAVI and
even E/e’ ratio between cirrhosis patients and the normal
controls should be emphasized (Fig. 1b and c). Any cut-
off value of LAVI or E/e’ ratio differentiating the two
groups could not be suggested. Besides, LV diastolic
function was not effectively categorised in approximately
50% of cirrhosis patients, suggesting that LV diastolic
function assessment with resting echocardiography is
neither practical nor sensitive approach for the diagnosis
of cirrhotic cardiomyopathy. This observation makes
sense given that overt structural changes in the LV are
not a prerequisite for LV diastolic dysfunction develop-
ment; simply, the aging process could lead to this change
[35]. Although dobutamine or exercise stress echocardi-
ography was suggested as alternative modalities to reveal
subclinical LV systolic/diastolic dysfunction [28], a
Fig. 3 Relationship between the degree of diffuse myocardial
fibrosis and cirrhosis severity. ECV denotes extracellular
volume fraction
Table 4 Individual patient pre-transplant native T2 value and ECV







ECV extracellular volume fraction
Table 5 Changes in electrocardiographic, echocardiographic
and CMR parameters in patients undergoing transplant
Pre-transplant 1 year post-transplant P value
Echocardiography
LVEF (%) 65.8 ± 5.0 62.5 ± 4.9 0.035
LV EDD (mm) 49.5 ± 4.7 46.0 ± 5.1 0.003
LV ESD (mm) 28.7 ± 3.9 27.9 ± 4.0 0.465
GLS (%) −24.9 ± 2.4 −20.6 ± 3.4 < 0.001
GCS (%) −28.4 ± 3.6 −24.6 ± 4.2 0.011
E/A ratio 1.18 ± 0.51 0.85 ± 0.27 0.002
E/e’ ratio 11.0 ± 0.23 8.9 ± 2.9 0.030
CMR
LV EDV (mL)_ 167 ± 48 130 ± 30 0.001
LV ESV (mL) 57 ± 22 48 ± 17 0.102
LVEF (%) 66.8 ± 6.8 65.1 ± 6.5 0.382
LV mass index (g/m2) 65.2 ± 9.3 59.5 ± 8.2 0.001
LV mass/LV-EDV ratio 0.7 ± 0.3 0.8 ± 0.1 0.028
Native T1 (msec) 1206 ± 72 1173 ± 73 0.121
ECV (%) 30.9 ± 4.5 25.4 ± 2.6 < 0.001
Electrocardiogram
QTc interval (msec) 475 ± 41 429 ± 30 0.001
Abbreviations as in Tables 2 and 3
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definite diagnosis of cirrhotic cardiomyopathy remains
challenging [2, 6].
QTc prolongation was also suggested as a component
of cirrhotic cardiomyopathy [27, 36]. Although the
mechanisms are unclear, cirrhosis progression seems to
be related to prolonged QTc, given that Child-Pugh
score showed a positive correlation with QTc interval.
Furthermore, we found that liver transplant normalized
QTc prolongation 1 year after transplant (Fig. 4d),
thereby showing a close relationship between the two.
Thus, QTc prolongation should alert physicians for the
possibility of cirrhotic cardiomyopathy; subsequently, ef-
forts to identify other evidences of cirrhotic cardiomyop-
athy should be made.
Myocardial structural alterations in cirrhosis
Data regarding myocardial histopathological changes in
cirrhosis are limited [37]. Most of earlier investigations
were conducted in an autopsy setting of alcoholic eti-
ology, and thus whether the findings are attributable to
alcoholic cardiomyopathy and whether similar findings
could be anticipated in an in vivo setting remain to be
established. CMR is best suited for this purpose with its
unique ability to characterise myocardial tissues. LGE
represents irreversible replacement fibrosis, while ECV
represents reversible DMF [10, 13]. As myocardial fibro-
sis is associated with cardiac hypertrophy and a stiff,
noncompliant LV [38], application of these two novel
CMR techniques is clinically relevant for the indirect as-
sessment of LV compliance or diastolic property. In this
study, irreversible LGE was observed only in one cirrho-
sis patient. Absence of coronary artery disease on pre-
operative computed tomographic or invasive coronary
angiography excluded the possibility of coronary disease
in all patients. On the other hand, we observed a signifi-
cant increment in ECV in cirrhosis, implying myocardial
extracellular volume expansion. Additionally, we noted a
significant relationship between ECV and cirrhosis se-
verity. All of these findings support the earlier observa-
tion by Wiese et al. (i.e., ECV increased in cirrhosis
patients) [8] and the concept of the heart-liver inter-
action [4, 39]. These observations highlight that an in-
creased ECV in cirrhosis signifies real myocardial
structural changes, thereby potentially representing a
Fig. 4 Liver transplantation-induced changes in ECV, global longitudinal strain (GLS), global circumferential strain (GCS) and electrocardiographic
QTc interval. ECV, extracellular volume fraction; GLS, global longitudinal strain; GCS, circumferential strain; QTc, corrected QT
Fig. 5 Changes of LV mass index (LVMI) and LV Mass / End-diastolic volume (EDV) ratio by cardiovascular magnetic resonance between pre- and
post-liver transplantation. LVMI, left ventricular mass index; LVM/EDV, left ventricular mass/end-diastolic volume
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structural component of cirrhotic cardiomyopathy. This is
of diagnostic value because current definition of cirrhotic
cardiomyopathy includes only functional, hemodynamic,
and electrocardiographic alterations, all of which are ex-
pected as secondary phenomena following structural alter-
ations. Of note, native T1 value did not change significantly
1-year post-transplant, which was in clear contrast to ECV.
This may be because native T1 value can be more affected
than ECV by factors other than DMF. Thus, assessment of
ECV is preferred to native T1 value to reliably detect myo-
cardial changes in cirrhosis. The mechanism underlying an
increased ECV is unclear. One possibility is that, in patients
with cirrhosis, effective circulatory volume decreases, as
portal hypertension progresses, and subsequently renin-
angiotensin aldosterone system is stimulated [40]. Given
that the renin-angiotensin aldosterone system is involved in
chronic tissue damage and diverse organ dysfunction in-
cluding myocardium [41], it is possible that DMF in cirrho-
sis is likely to be related to the activation of renin-
angiotensin aldosterone system.
The interpretation that increased ECV in cirrhosis rep-
resents DMF may be debatable because increased intra-
vascular volume can expand myocardial extracellular
space, thereby resulting in an increased ECV. However,
as cirrhosis progresses, redistribution of blood volume
occurs with a decrease in the central circulation (i.e.
central hypovolemia) and an increase of blood volume in
splanchnic bed [1]. In this setting, increased myocardial
intravascular volume is unlikely to occur. Moreover, the
observation of a stepwise increase in ECV from healthy
subjects, Child-Pugh class A/B, to Child-Pugh class C
does not support the hypothesis that increased intravas-
cular volume may be responsible for increased ECV.
Pathologic data also suggests that DMF should be major
myocardial structural changes in cirrhosis; Lunseth and
colleagues found delicate DMF in 99 autopsied cirrhosis
cases [9]. They described that the interposition of deli-
cate fibrous tissues was frequently noted in the gap
caused by transversely ruptured muscle fibers, however
exudation or edema was present in only two cases [9].
Additionally, a previous study demonstrated that pa-
tients with myocardial edema showed decreased GLS re-
gardless of LVEF [42]. Furthermore, we observed that
the pre-transplant native T2 values assessed in 6 patients
were all within normal ranges. Taken together, it is
highly likely that increased ECV on CMR in cirrhosis pa-
tients predominantly represents DMF.
Transplant-induced structural, functional, and
electrocardiographic changes
Liver transplantation is the only curative treatment and
has been believed to reverse structural, hemodynamic,
Fig. 6 Myocardial structural, functional, and electrophysiological changes pre- and post-liver transplantation. ECV, extracellular volume fraction;
GLS, left ventricular global longitudinal strain; QTc, corrected QT interval
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and functional cardiac alterations in cirrhosis. However,
only two prospective studies investigated transplant-
induced cardiac changes. In the first study, 19 patients
were evaluated with echocardiography before and 6 to
12months after transplant. The authors found that
transplant resulted in LV wall thickness regression, and
a decrease in cardiac index and LVEF, but no change in
LV diastolic function indexes [26]. The second study eval-
uated 40 patients with echocardiography before and 3
months after transplant. They observed LV diastolic func-
tion deterioration [43]. The main discrepancy between the
two studies is regarding LV diastolic function, which im-
plies practical difficulties in LV diastolic function assess-
ment with echocardiography. Although echocardiography
is currently the best non-invasive tool [19, 35], echocar-
diographic transmitral inflow velocities are difficult to in-
terpret in the setting of LV load changes such as in
transplantation [44]. Recognition of this limitation led us
to focus on the hemodynamic, systolic functional, and
structural changes in the LV. Interestingly, echocardio-
graphic GLS in cirrhosis was significantly augmented pre-
transplant, and normalized 1-year post-transplant. Fur-
thermore, a change in GLS was accompanied by a signifi-
cant ECV reduction and QTc normalization (Table 5).
Augmented GLS at rest in cirrhosis could be explained
by the resting recruitment of LV contractile reserve to
maintain hyper-dynamic circulation [31]. Resting re-
cruitment of LV contractile reserve is potentially associ-
ated with a blunted inotropic response to physical or
pharmacological stress that is previously described as a
characteristic component of cirrhotic cardiomyopathy.
Augmented GLS and increased ECV pre-transplant were
normalized 1-year post-transplant, suggesting that GLS
and ECV assessment could provide a good opportunity
to sensitively and early detect transplant-induced minute
changes in LV ultrastructure as well as systolic function.
Interestingly, despite limited number of patients ana-
lysed, elevated ECV pre-transplant was fully reversible 1-
year post-transplant in all cirrhosis patients. Thus, ECV
estimation would not be required to confirm the restor-
ation of myocardial health post-transplant.
We observed a stepwise increase in ECV from healthy
subjects, Child-Pugh class A/B, to Child-Pugh class C,
suggesting that ECV quantification can be clinically used
to track myocardial health in relation to cirrhosis sever-
ity. Detection of this unique cardiomyopathy pre-
transplant is clinically relevant and important given that
up to 25% of cirrhosis patients were reported to experi-
ence cardiac death after transplant [1]. Of note, however,
statistical significance was not achieved between the nor-
mal controls and cirrhosis patients with Child-Pugh class
A/B, suggesting that early detection with CMR alone
may be clinically challenging even if myocardial alter-
ation begins at the early stage of cirrhosis. Further
efforts should be made to more sensitively detect early
stage of DMF in cirrhosis patients.
Study limitations
Firstly, patients were enrolled in a prospective manner,
but we had to exclude patients who could not undergo
CMR, i.e. poor renal function or patients with acute clin-
ical deterioration. Thus, our results could not be gener-
alized to all terminally decompensated cirrhosis patients.
Secondly, we did not demonstrate potential associations
between CMR findings and long-term clinical outcomes.
Finally, this study cannot provide definite clinical man-
agement directions to reduce the risk of cardiovascular
events peri-operatively.
Conclusions
Myocardial extracellular expansion with augmented resting
LV systolic function was a characteristic finding in cirrhotic
cardiomyopathy. This cardiac change was reversible 1 year
after liver transplantation, suggesting that hepatic decom-
pensation itself should be a culprit for the cause of the ob-
served myocardial structural and functional changes. Thus,
myocardial extracellular expansion represents a structural
component of myocardial change in cirrhosis.
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